Viking Therapeutics initiates Phase 1 study for oral GLP-1/GIP agonist VK2735; data expected H2 2023

Viking Therapeutics, Inc.

Phase 1 trial of oral VK2735 tablet, dual GLP-1/GIP receptor agonist, in healthy adults with BMI ≥30.
Randomized, double-blind, placebo-controlled study evaluating daily oral doses for 28 days.
Primary objective: safety and tolerability; exploratory measures include body weight and plasma glucose.
Top-line data anticipated in the second half of 2023.
Prior subcutaneous Phase 1 showed up to 7.8% mean weight loss; Phase 2 for subcutaneous formulation planned for mid-2023.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.